Do analysts prefer TVGN or SCLX?

Tevogen Bio presently has a consensus price target of $100.00, suggesting a potential upside of 2,127.17%. Given Tevogen Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Tevogen Bio is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TVGN or SCLX more profitable?

Tevogen Bio has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -472.77% Scilex -1,110.17% N/A -143.55%

Does the media favor TVGN or SCLX?

In the previous week, Tevogen Bio had 1 more articles in the media than Scilex. MarketBeat recorded 3 mentions for Tevogen Bio and 2 mentions for Scilex. Scilex's average media sentiment score of 1.25 beat Tevogen Bio's score of 0.87 indicating that Scilex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tevogen Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scilex 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TVGN or TELO?

Tevogen Bio currently has a consensus target price of $100.00, suggesting a potential upside of 2,127.17%. Given Tevogen Bio's higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, TVGN or TELO?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tevogen Bio N/A N/A -$26.27M -$4.61 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A

Is TVGN or TELO more profitable?

Tevogen Bio's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -472.77% Telomir Pharmaceuticals N/A -201.23% -172.71%

Does the media favor TVGN or TELO?

In the previous week, Tevogen Bio and Tevogen Bio both had 3 articles in the media. Telomir Pharmaceuticals' average media sentiment score of 1.08 beat Tevogen Bio's score of 0.87 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tevogen Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telomir Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, TVGN or CING?

Cingulate is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tevogen Bio N/A N/A -$26.27M -$4.61 N/A Cingulate N/A N/A -$22.45M -$4.23 N/A

Is TVGN or CING more profitable?

Tevogen Bio's return on equity of 0.00% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -472.77% Cingulate N/A -365.15% -158.55%

Does the media prefer TVGN or CING?

In the previous week, Tevogen Bio had 1 more articles in the media than Cingulate. MarketBeat recorded 3 mentions for Tevogen Bio and 2 mentions for Cingulate. Cingulate's average media sentiment score of 1.28 beat Tevogen Bio's score of 0.87 indicating that Cingulate is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tevogen Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cingulate 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TVGN or IMA more profitable?

Tevogen Bio's return on equity of 0.00% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -472.77% ImageneBio N/A -38.96% -34.60%

Does the media favor TVGN or IMA?

In the previous week, Tevogen Bio had 1 more articles in the media than ImageneBio. MarketBeat recorded 3 mentions for Tevogen Bio and 2 mentions for ImageneBio. ImageneBio's average media sentiment score of 1.43 beat Tevogen Bio's score of 0.87 indicating that ImageneBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tevogen Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImageneBio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TCRX or TVGN?

In the previous week, TScan Therapeutics and TScan Therapeutics both had 3 articles in the media. Tevogen Bio's average media sentiment score of 0.87 beat TScan Therapeutics' score of 0.44 indicating that Tevogen Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tevogen Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tevogen Bio (TVGN) Competitors

$4.49 +0.08 (+1.81%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$4.14 -0.35 (-7.71%)

As of 07/24/2026 07:26 PM Eastern

Compare

TVGN vs. SCLX, TELO, CING, IMA, and TCRX

Should you buy Tevogen Bio stock or one of its competitors? MarketBeat compares Tevogen Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tevogen Bio include Scilex (SCLX), Telomir Pharmaceuticals (TELO), Cingulate (CING), ImageneBio (IMA), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry.

How does Tevogen Bio compare to Scilex?

Tevogen Bio (NASDAQ:TVGN) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Tevogen Bio has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
Scilex	-1,110.17%	N/A	-143.55%

Tevogen Bio presently has a consensus price target of $100.00, suggesting a potential upside of 2,127.17%. Given Tevogen Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Tevogen Bio is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Tevogen Bio had 1 more articles in the media than Scilex. MarketBeat recorded 3 mentions for Tevogen Bio and 2 mentions for Scilex. Scilex's average media sentiment score of 1.25 beat Tevogen Bio's score of 0.87 indicating that Scilex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scilex	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.7% of Scilex shares are owned by institutional investors. 70.5% of Tevogen Bio shares are owned by insiders. Comparatively, 4.5% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tevogen Bio has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Scilex has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

Tevogen Bio has higher earnings, but lower revenue than Scilex. Tevogen Bio is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
Scilex	$30.25M	1.92	-$358.73M	-$40.47	N/A

Summary

Tevogen Bio beats Scilex on 7 of the 13 factors compared between the two stocks.

How does Tevogen Bio compare to Telomir Pharmaceuticals?

Tevogen Bio (NASDAQ:TVGN) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Tevogen Bio has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

Tevogen Bio's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Tevogen Bio currently has a consensus target price of $100.00, suggesting a potential upside of 2,127.17%. Given Tevogen Bio's higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

In the previous week, Tevogen Bio and Tevogen Bio both had 3 articles in the media. Telomir Pharmaceuticals' average media sentiment score of 1.08 beat Tevogen Bio's score of 0.87 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telomir Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Telomir Pharmaceuticals beats Tevogen Bio on 6 of the 10 factors compared between the two stocks.

How does Tevogen Bio compare to Cingulate?

Tevogen Bio (NASDAQ:TVGN) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

In the previous week, Tevogen Bio had 1 more articles in the media than Cingulate. MarketBeat recorded 3 mentions for Tevogen Bio and 2 mentions for Cingulate. Cingulate's average media sentiment score of 1.28 beat Tevogen Bio's score of 0.87 indicating that Cingulate is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cingulate	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cingulate is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

Tevogen Bio currently has a consensus target price of $100.00, indicating a potential upside of 2,127.17%. Cingulate has a consensus target price of $27.33, indicating a potential upside of 489.08%. Given Tevogen Bio's higher possible upside, research analysts plainly believe Tevogen Bio is more favorable than Cingulate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Tevogen Bio has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.91, indicating that its share price is 191% less volatile than the broader market.

Tevogen Bio's return on equity of 0.00% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
Cingulate	N/A	-365.15%	-158.55%

41.3% of Cingulate shares are owned by institutional investors. 70.5% of Tevogen Bio shares are owned by insiders. Comparatively, 5.3% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Cingulate beats Tevogen Bio on 7 of the 13 factors compared between the two stocks.

How does Tevogen Bio compare to ImageneBio?

Tevogen Bio (NASDAQ:TVGN) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Tevogen Bio has higher earnings, but lower revenue than ImageneBio. Tevogen Bio is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
ImageneBio	$800K	74.42	-$45.35M	-$5.79	N/A

Tevogen Bio's return on equity of 0.00% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
ImageneBio	N/A	-38.96%	-34.60%

75.0% of ImageneBio shares are owned by institutional investors. 70.5% of Tevogen Bio shares are owned by company insiders. Comparatively, 2.2% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tevogen Bio has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Tevogen Bio presently has a consensus price target of $100.00, suggesting a potential upside of 2,127.17%. ImageneBio has a consensus price target of $30.00, suggesting a potential upside of 436.67%. Given Tevogen Bio's higher possible upside, equities analysts clearly believe Tevogen Bio is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

In the previous week, Tevogen Bio had 1 more articles in the media than ImageneBio. MarketBeat recorded 3 mentions for Tevogen Bio and 2 mentions for ImageneBio. ImageneBio's average media sentiment score of 1.43 beat Tevogen Bio's score of 0.87 indicating that ImageneBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImageneBio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ImageneBio beats Tevogen Bio on 8 of the 14 factors compared between the two stocks.

How does Tevogen Bio compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

TScan Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

Tevogen Bio has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. Tevogen Bio's return on equity of 0.00% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Tevogen Bio	N/A	N/A	-472.77%

TScan Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 655.67%. Tevogen Bio has a consensus target price of $100.00, suggesting a potential upside of 2,127.17%. Given Tevogen Bio's higher possible upside, analysts plainly believe Tevogen Bio is more favorable than TScan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Tevogen Bio has lower revenue, but higher earnings than TScan Therapeutics. Tevogen Bio is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	5.03	-$129.77M	-$0.96	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

In the previous week, TScan Therapeutics and TScan Therapeutics both had 3 articles in the media. Tevogen Bio's average media sentiment score of 0.87 beat TScan Therapeutics' score of 0.44 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tevogen Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.8% of TScan Therapeutics shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by insiders. Comparatively, 70.5% of Tevogen Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

TScan Therapeutics beats Tevogen Bio on 8 of the 14 factors compared between the two stocks.

Get Tevogen Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVGN vs. The Competition

Export

Metric	Tevogen Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.80M	$3.67B	$7.07B	$12.22B
Dividend Yield	N/A	2.18%	2.67%	9.42%
P/E Ratio	-0.97	21.29	27.14	23.62
Price / Sales	N/A	298.37	523.79	89.78
Price / Cash	N/A	59.51	26.39	46.67
Price / Book	-0.02	7.89	10.30	6.08
Net Income	-$26.27M	$23.81M	$3.60B	$331.70M
7 Day Performance	6.65%	-3.82%	-1.27%	-0.63%
1 Month Performance	-35.86%	-4.45%	-1.67%	-3.04%
1 Year Performance	-91.53%	33.01%	18.25%	13.30%

Tevogen Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVGN Tevogen Bio	1.6112 of 5 stars	$4.49 +1.8%	$100.00 +2,127.2%	-91.5%	$18.80M	N/A	N/A	3	News Coverage
SCLX Scilex	0.5495 of 5 stars	$7.84 +2.6%	N/A	-42.8%	$64.87M	$30.25M	N/A	80	Positive News
TELO Telomir Pharmaceuticals	0.4501 of 5 stars	$1.08 +17.5%	N/A	-47.5%	$63.22M	N/A	N/A	1	High Trading Volume
CING Cingulate	2.4555 of 5 stars	$4.78 +4.8%	$27.33 +471.8%	-15.6%	$61.42M	N/A	N/A	20	News Coverage Positive News Analyst Upgrade
IMA ImageneBio	2.6188 of 5 stars	$6.00 +4.7%	$26.50 +341.7%	-67.4%	$61.05M	$800K	N/A	70	News Coverage Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVGN) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tevogen Bio (TVGN) Competitors

TVGN vs. SCLX, TELO, CING, IMA, and TCRX

How does Tevogen Bio compare to Scilex?

Summary

How does Tevogen Bio compare to Telomir Pharmaceuticals?

Summary

How does Tevogen Bio compare to Cingulate?

Summary

How does Tevogen Bio compare to ImageneBio?

Summary

How does Tevogen Bio compare to TScan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN vs. The Competition

Tevogen Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tevogen Bio (TVGN) Competitors

TVGN vs. SCLX, TELO, CING, IMA, and TCRX

How does Tevogen Bio compare to Scilex?

Is TVGN or SCLX more profitable?

Do analysts prefer TVGN or SCLX?

Does the media favor TVGN or SCLX?

Do institutionals and insiders have more ownership in TVGN or SCLX?

Which has more risk & volatility, TVGN or SCLX?

Which has stronger earnings & valuation, TVGN or SCLX?

Summary

How does Tevogen Bio compare to Telomir Pharmaceuticals?

Which has more risk and volatility, TVGN or TELO?

Is TVGN or TELO more profitable?

Do analysts prefer TVGN or TELO?

Which has preferable earnings & valuation, TVGN or TELO?

Does the media favor TVGN or TELO?

Summary

How does Tevogen Bio compare to Cingulate?

Does the media prefer TVGN or CING?

Which has preferable valuation and earnings, TVGN or CING?

Do analysts prefer TVGN or CING?

Which has more volatility and risk, TVGN or CING?

Is TVGN or CING more profitable?

Do insiders & institutionals hold more shares of TVGN or CING?

Summary

How does Tevogen Bio compare to ImageneBio?

Which has better valuation & earnings, TVGN or IMA?

Is TVGN or IMA more profitable?

Do insiders and institutionals have more ownership in TVGN or IMA?

Which has more volatility and risk, TVGN or IMA?

Do analysts recommend TVGN or IMA?

Does the media favor TVGN or IMA?

Summary

How does Tevogen Bio compare to TScan Therapeutics?

Which has more risk and volatility, TCRX or TVGN?

Is TCRX or TVGN more profitable?

Do analysts rate TCRX or TVGN?

Which has preferable earnings & valuation, TCRX or TVGN?

Does the media refer more to TCRX or TVGN?

Do insiders & institutionals hold more shares of TCRX or TVGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN vs. The Competition

Tevogen Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools